查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2000762

海洋生物技術市場：全球市場按產品類型、原料、技術、應用和最終用戶分類的預測 - 2026-2032 年

Marine Biotechnology Market by Product Type, Source, Technology, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，海洋生物技術市場價值將達到 88.8 億美元，到 2026 年將成長到 95.3 億美元，到 2032 年將達到 150 億美元，複合年成長率為 7.77%。

主要市場統計數據
基準年 2025 88.8億美元
預計年份：2026年 95.3億美元
預測年份 2032 150億美元
複合年成長率 (%) 7.77%

以科學突破、轉化途徑和對永續性的需求為驅動力，對充滿活力的海洋生物技術領域進行策略性展望。

海洋生物技術領域正處於一個轉折點，科學創新與緊迫的商業性和環境需求在此交匯融合。分子生物學、體學平台和生物製程工程的快速發展，使得人們能夠發現和開發源自海洋的新型化合物和材料；同時，分析技術的進步也開啟了以往難以取得的生物多樣性。因此，研究機構、工業研發和政策制定等各相關人員都在重新思考如何從海洋生物資源創造價值。

技術創新、永續性需求和跨部門合作如何重塑海洋生物技術領域的機會和競爭優勢。

海洋生物技術領域正經歷著變革性的轉變，這主要得益於技術的成熟、政策的演變以及市場的融合。高通量定序和無培養技術的進步使得無需依賴可培養生物體即可進行快速生物探勘，從而拓展了可獲取分子的多樣性。與此同時，分離和培養調查方法的改進正在彌合從發現到規模化生產的鴻溝，最終帶來更可預測的產量和更有效率的下游製程。

了解 2025 年關稅措施將如何改變整個海洋生物技術價值鏈的採購、供應鏈韌性和策略夥伴關係。

主要貿易夥伴的政策干預可能會顯著改變整個海洋生物技術領域的供應鏈動態、研究合作模式和成本結構。 2025年宣布的關稅的累積影響將波及所有採購管道，影響原料採購、國際夥伴關係和下游位置等方面的決策。嚴重依賴跨境供應路線和專業中間體的企業已被迫重新評估供應商多樣性和物流韌性，以應對不斷飆升的交易成本和延誤。

詳細的細分分析突顯了基於產品類型、生物原料、底層技術、應用和最終用戶需求的不同商業化路徑。

細分市場趨勢表明，商業化路徑因產品原型、生物原料、底層技術、應用領域和最終用戶需求而異。就產品類型而言，生物活性化合物因其治療潛力和功能性而持續成為研發重點，而生物材料作為包裝、醫療設備和工業基材的永續替代品也備受關注。這兩個領域需要不同的商業化策略。生物活性化合物需要大量的安全性和有效性證據才能進入製藥領域，而生物材料則更注重規模化、性能基準測試以及與現有生產系統的整合。

從區域比較的角度解釋生物多樣性、監管環境和產業能力如何塑造世界各地海洋生物技術的不同發展軌跡。

海洋生物技術的區域發展趨勢受到生物多樣性、管理體制、投資環境和產業能力差異的影響。在美洲，從溫帶到熱帶水域的生態系統孕育著豐富的生物資源，公共和私人投資正日益集中於轉化研究基礎設施、中試規模設施以及連接學術界和產業界的創新叢集。這些發展正在提升國內海洋生物資源的附加價值，並促進沿海州與內陸製造地之間的合作。

專有平台、模組化製造投資和策略合作夥伴關係如何塑造該產業的競爭優勢和商業化路徑？

該領域的競爭動態由獨特的科學技術、平台能力和策略夥伴關係關係相互作用所決定。領先機構將深厚的生物學專業知識與可擴展的程式工程和監管經驗相結合，以推動複雜的產品開發流程。學術機構與私人企業之間的合作十分普遍，技術轉移辦公室和授權協議彌合了科學研究發現與商業開發專案之間的鴻溝。

為高階主管提供切實可行的策略步驟，以協調發現平台、彈性採購結構和協作商業化，從而加速產生影響並降低營運風險。

海洋生物技術領域的領導企業應採取一系列切實可行的措施，將科學研究潛力轉化為永續的商業性成果。首先，它們應優先考慮將藥物發現平台與下游開發相結合，以縮短實用化時間並降低規模化生產風險。這意味著要使早期篩檢標準與可生產性指標和監管要求一致，確保候選藥物的選擇能反映出端到端的可行性。

採用透明、多方面的研究途徑，結合專家訪談、文獻整合、專利分析和區域比較案例研究來檢驗見解。

本執行摘要的研究採用了多方面方法，結合定性和定量分析，以確保獲得全面可靠的見解。初步研究包括對相關行業專家、研發負責人、監管顧問和高階主管進行深度訪談，以了解當前的優先事項、營運挑戰和策略意圖。這些對話為理解各組織如何根據技術和政策變化調整其藥物研發、規模化生產和市場拓展活動提供了背景資訊。

最終評估強調轉化嚴謹性、永續採購和夥伴關係是海洋生物技術長期成功的決定因素。

海洋生物技術佔據著一個獨特的領域，它融合了科學潛力和社會需求，為健康、永續性和產業轉型提供解決方案。無論產品類型或地理為何，發展方向都十分明確：轉化卓越性、可靠的資源取得和策略夥伴關係決定著哪些舉措能夠從實驗室發現走向商業性成功。諸如無培養技術和改進的培養方法等技術進步正在拓展潛在候選產品的範圍，但成功取決於將這些創新與穩健的生產製造和合規策略相結合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 海洋生技市場：依產品類型分類

  • 生物活性化合物
  • 生物材料

第9章 海洋生物技術市場：依來源分類

  • 珊瑚和海綿
  • 海藻
  • 海洋真菌
  • 海洋病毒

第10章 海洋生物技術市場：依技術分類

  • 一種不需要文化的技術
  • 微生物的分離與培養

第11章 海洋生物技術市場：依應用領域分類

  • 水產養殖/漁業
  • 生質燃料
  • 藥物發現
  • 環境衛生與人體健康
  • 食品供應
  • 工業產品和工藝

第12章 海洋生物技術市場：依最終用戶分類

  • 化學
  • 化妝品
  • 能源
  • 食品工業
  • 醫療和製藥

第13章 海洋生物技術市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 海洋生物技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 海洋生物技術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國海洋生物技術市場

第17章：中國海洋生物技術市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aker BioMarine ASA
  • BASF SE
  • Biolchim Group by JM Huber Corporation
  • BioLume, Inc.
  • BlueBioTech GmbH
  • Cellana Inc.
  • Corbion NV
  • DSM-Firmenich AG
  • Earthrise Nutritionals LLC
  • GeoMarine Biotechnologies（P）LTD
  • GlycoMar Ltd.
  • Marine Biopolymers Ltd.
  • Marinova Pty Ltd
  • Marshall Marine Products
  • Nofima
  • oceanBASIS GmbH
  • Pharma Mar, SA
  • PROLUME, LTD
  • Seppic SA
  • The GELITA Group
  • Veramaris VOF
  • Xanthella Ltd.
  • ZIVO Bioscience, Inc.
Product Code: MRR-02026C4C9A70

The Marine Biotechnology Market was valued at USD 8.88 billion in 2025 and is projected to grow to USD 9.53 billion in 2026, with a CAGR of 7.77%, reaching USD 15.00 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.88 billion
Estimated Year [2026] USD 9.53 billion
Forecast Year [2032] USD 15.00 billion
CAGR (%) 7.77%

A strategic orientation to the dynamic marine biotechnology arena driven by scientific breakthroughs, translational pipelines, and sustainability imperatives

The marine biotechnology sector stands at an inflection point where scientific innovation converges with pressing commercial and environmental imperatives. Rapid progress in molecular biology, omics platforms, and bioprocess engineering is enabling the discovery and development of novel compounds and materials from marine sources, while parallel advances in analytical technologies are unlocking previously inaccessible biodiversity. Consequently, stakeholders across research institutions, industrial R&D, and policy realms are recalibrating strategies to capture value from the ocean's biological resources.

Given this context, the industry is witnessing a shift from exploratory science to translational pipelines, where early-stage discoveries are increasingly assessed for scale-up, regulatory viability, and market fit. At the same time, heightened attention to sustainability and circularity is influencing sourcing strategies and product design, prompting collaborations between ecologists, chemists, and process engineers. As a result, the landscape offers both opportunity and complexity: innovation potential is high, but so are the challenges around reproducible supply, regulatory alignment, and cross-sector adoption.

Looking ahead, decision-makers must balance long-term research investments with near-term commercialization pathways. This requires an integrated view that connects scientific trajectories with supply chain realities and end-user needs. Accordingly, executives should prioritize translational frameworks that de-risk scale-up, foster interdisciplinary partnerships, and align product pipelines with evolving regulatory and societal expectations.

How converging technological innovations, sustainability mandates, and cross-sector collaborations are reshaping opportunity and competitive advantage in marine biotechnology

The landscape of marine biotechnology is undergoing transformative shifts driven by technological maturation, policy evolution, and market convergence. Advances in high-throughput sequencing and culture-independent techniques are enabling rapid bioprospecting without the historical dependence on cultivable organisms, thereby broadening the accessible molecular diversity. At the same time, improvements in isolation and cultivation methodologies are closing the gap between discovery and scalable production, enabling more predictable yields and streamlined downstream processing.

Concurrently, regulatory trends and public expectations are accelerating the adoption of sustainability frameworks, which in turn influence sourcing strategies and product claims. Cross-sector collaborations are emerging as a key mechanism to translate lab-scale innovations into commercial products, with chemical, cosmetic, food, energy, and pharmaceutical companies increasingly participating in co-development and licensing agreements. Moreover, the intersection of digital tools, such as AI-driven compound screening and process modeling, is shortening development cycles and enabling more informed portfolio decisions.

As these forces coalesce, competitive advantage will accrue to organizations that integrate advanced analytical platforms with robust bioprocess capabilities and clear sustainability narratives. Therefore, effective strategies will emphasize modular scale-up approaches, strategic partnerships for supply assurance, and transparent lifecycle assessments to satisfy both regulators and consumers.

Understanding how 2025 tariff measures have shifted sourcing, supply chain resilience, and strategic partnerships across marine biotechnology value chains

Policy interventions from major trading partners can significantly alter supply chain dynamics, research collaboration patterns, and cost structures across marine biotechnology sectors. The cumulative impact of tariffs announced in 2025 has reverberated across procurement channels, influencing decisions about raw material sourcing, international partnerships, and location choices for downstream processing. Organizations that relied on transnational supply routes or specialized intermediates have had to reassess supplier diversity and logistical resilience to mitigate elevated transaction costs and delays.

In response, many stakeholders accelerated nearshoring and regionalization of critical activities to reduce exposure to tariff volatility. This trend has prompted investments in local cultivation capabilities, onshore bioprocessing facilities, and domestic talent development to secure continuity of supply and maintain regulatory control over biologically sensitive materials. At the same time, funding mechanisms and collaborative consortia emerged to underwrite the cost of transitioning to more resilient architectures, often leveraging public-private partnerships to spread risk.

Importantly, the policy environment also influenced strategic partnerships, with firms prioritizing agreements that could internalize value across the value chain and minimize cross-border transfers of intermediate products. Accordingly, companies are reframing sourcing strategies to emphasize diversification, contractual protections, and vertically integrated models that balance cost, compliance, and continuity requirements.

Detailed segmentation analysis highlighting divergent commercialization routes across product types, biological sources, enabling technologies, applications, and end-user demands

Segment-level dynamics reveal differentiated pathways to commercialization that depend on product archetype, biological source, enabling technology, application domain, and end-user requirements. In the realm of product types, bioactive compounds continue to attract intensive R&D focus due to their therapeutic potential and functional properties, while biomaterials are drawing interest for sustainable alternatives in packaging, medical devices, and industrial substrates. These two vectors require distinct commercialization strategies: bioactives demand extensive safety and efficacy evidence to engage pharmaceutical pathways, whereas biomaterials emphasize scale, performance benchmarking, and integration with existing manufacturing systems.

Turning to biological sources, corals and sponges remain prized for their chemical novelty, marine algae offer an abundant and renewable feedstock for both bioactives and biomaterials, marine fungi present unique enzymatic capabilities for biotransformation, and marine viruses are emerging as precision tools for molecular delivery and ecosystem monitoring. Each source imposes specific constraints on sampling, regulatory permitting, and cultivation approaches, which in turn shape R&D timelines.

On the technology front, culture-independent techniques are accelerating discovery by enabling access to uncultured diversity and rapid candidate identification, while isolation and cultivation of microorganisms remain essential for downstream development, scale-up, and reproducible production. Applications span aquaculture and fishery innovation, biofuels development, drug discovery pipelines, environmental and human health interventions, food supply enhancements, and industrial products and processes, each with unique validation pathways and stakeholder expectations. Finally, end-user segments such as chemical manufacturers, cosmetics companies, energy firms, the food industry, and medical and pharmaceutical organizations drive different specifications, regulatory burdens, and commercial timing, meaning that product development strategies must be tailored to the ultimate customer and use case.

Comparative regional outlook describing how biodiversity, regulatory landscapes, and industrial capabilities shape distinct marine biotechnology trajectories across global geographies

Regional dynamics in marine biotechnology are shaped by disparities in biodiversity, regulatory regimes, investment climates, and industrial capabilities. In the Americas, ecosystems ranging from temperate to tropical waters support a diverse array of biological resources, while public and private investment has increasingly targeted translational infrastructure, pilot-scale facilities, and innovation clusters that bridge academy and industry. These developments are enabling more domestic valorization of marine bioresources and fostering collaborations between coastal states and inland manufacturing hubs.

Europe, Middle East & Africa presents a mosaic of regulatory environments and scientific capacity. European markets often lead in rigorous environmental and product safety frameworks, which can raise barriers but also create predictable pathways for high-value products. The Middle East is investing in blue economy initiatives that prioritize desalination byproducts and algae cultivation, whereas various African nations offer rich biodiversity and growing interest in leveraging marine bioresources for local economic development. Across this region, capacity building, benefit-sharing agreements, and ethical sourcing practices are increasingly central to project design.

Asia-Pacific combines robust manufacturing ecosystems with expansive coastal biodiversity and rapidly evolving research capabilities. Several nations in the region are scaling aquaculture-based supply chains, investing in bioprocessing capacity, and fostering start-up ecosystems that translate marine discoveries into consumer goods and industrial inputs. Consequently, the Asia-Pacific region is becoming a critical node for both upstream discovery and downstream manufacture, reflecting a balance between resource availability and industrial deployment.

How proprietary platforms, modular manufacturing investments, and strategic alliances are shaping competitive advantage and commercialization pathways in the sector

Competitive dynamics within the sector are defined by an interplay of proprietary science, platform capabilities, and strategic partnerships. Leading organizations combine deep biological expertise with scalable process engineering and regulatory experience to navigate complex product development pathways. Collaborations between academic centers and commercial entities are common, with technology transfer offices and licensing arrangements serving as conduits for moving discoveries into commercial development programs.

Additionally, firms that have invested in modular scale-up facilities and flexible manufacturing platforms gain an edge in de-risking early-stage assets and accelerating time-to-market for diverse product classes. Intellectual property strategies increasingly focus on platform-level protections as well as compound-specific claims to maximize portfolio value. At the same time, strategic alliances with end-user incumbents in chemicals, cosmetics, food, energy, and pharmaceuticals help validate market fit and provide channels for distribution and co-development.

Smaller, specialized players often compete on agility and niche expertise, driving innovation in discovery methods or specific product classes, while larger industrial actors bring the resources necessary for global scale and regulatory navigation. This competitive mix underscores the importance of strategic collaborations that pair scientific novelty with commercialization muscle, enabling a continuum from laboratory innovation to market deployment.

Actionable strategic steps for executives to align discovery platforms, resilient sourcing, and collaborative commercialization to accelerate impact and mitigate operational risks

Leaders in marine biotechnology should adopt a set of pragmatic actions to translate scientific promise into sustainable commercial outcomes. First, prioritize the integration of discovery platforms with downstream process development to shorten the translation timeline and reduce scale-up risk. This means aligning early-stage screening criteria with manufacturability metrics and regulatory considerations so that candidate selection reflects end-to-end feasibility.

Second, diversify sourcing strategies by combining sustainable wild-harvest policies with cultivation and fermentation-based production methods to ensure supply continuity, ecological stewardship, and compliance with access and benefit-sharing obligations. In parallel, invest in regional partnerships and nearshore facilities to insulate operations from geopolitical and tariff-driven disruptions.

Third, build cross-sector partnerships that couple domain expertise with market access; for instance, co-development agreements with cosmetic or food industry incumbents can validate functionality and accelerate adoption. Fourth, implement robust IP and data management strategies that protect platform innovations while enabling selective licensing and collaborative research. Finally, emphasize transparent sustainability credentials and lifecycle assessments to meet regulatory demands and consumer expectations, thereby strengthening brand positioning and long-term market acceptance.

Transparent multi-method research approach combining expert interviews, literature synthesis, patent analysis, and comparative regional case studies to validate insights

The research behind this executive synthesis employed a multi-method approach combining qualitative and quantitative analyses to ensure comprehensive, reliable insights. Primary research consisted of in-depth interviews with subject-matter experts, R&D leaders, regulatory advisers, and senior executives across relevant industry verticals to capture current priorities, operational challenges, and strategic intent. These conversations provided context for understanding how organizations are adapting discovery, scale-up, and go-to-market activities in response to technological and policy shifts.

Secondary research entailed a systematic review of peer-reviewed literature, patent landscapes, public policy documents, and corporate disclosures to triangulate trends and validate thematic patterns observed in primary interviews. The methodology further incorporated case study assessments of representative initiatives spanning bioactive discovery, biomaterials development, and platform commercialization to illustrate practical pathways and common bottlenecks.

Finally, the analysis applied a comparative regional lens to account for variation in regulatory frameworks, biodiversity endowments, and industrial capacity. Throughout, findings were synthesized using an evidence-based framework that prioritizes corroboration across data sources and transparent documentation of assumptions, thereby providing decision-makers with a defensible basis for strategic planning.

Concluding assessment emphasizing translational rigor, sustainable sourcing, and partnerships as the critical determinants of long-term success in marine biotechnology

Marine biotechnology occupies a unique intersection of scientific potential and societal need, offering solutions that span health, sustainability, and industrial transformation. Across product classes and geographies, the trajectory is clear: translational excellence, resilient sourcing, and strategic partnerships will determine which initiatives progress from laboratory discovery to commercial impact. While technological advances such as culture-independent techniques and improved cultivation methods broaden the universe of viable candidates, success depends on integrating these innovations with robust manufacturing and regulatory strategies.

In sum, stakeholders who invest in platform capabilities, foster interdisciplinary collaborations, and maintain a disciplined focus on sustainability and supply chain resilience will be best positioned to capture long-term value. The pace of innovation coupled with regulatory evolution creates both urgency and opportunity for organizations willing to adopt adaptive commercialization models and to engage constructively with policy frameworks. Ultimately, the path forward requires a blend of scientific rigor, operational pragmatism, and strategic partnerships that align discovery with market realities and societal expectations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Marine Biotechnology Market, by Product Type

  • 8.1. Bioactive Compounds
  • 8.2. Biomaterials

9. Marine Biotechnology Market, by Source

  • 9.1. Corals & Sponges
  • 9.2. Marine Algae
  • 9.3. Marine Fungi
  • 9.4. Marine Viruses

10. Marine Biotechnology Market, by Technology

  • 10.1. Culture-Independent Techniques
  • 10.2. Isolation & Cultivation of Microorganisms

11. Marine Biotechnology Market, by Application

  • 11.1. Aquaculture & Fishery
  • 11.2. Biofuels
  • 11.3. Drug Discovery
  • 11.4. Environmental Health & Human Health
  • 11.5. Food supply
  • 11.6. Industrial Products & Processes

12. Marine Biotechnology Market, by End-User

  • 12.1. Chemical
  • 12.2. Cosmetics
  • 12.3. Energy
  • 12.4. Food Industry
  • 12.5. Medical & Pharmaceutical

13. Marine Biotechnology Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Marine Biotechnology Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Marine Biotechnology Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Marine Biotechnology Market

17. China Marine Biotechnology Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aker BioMarine ASA
  • 18.6. BASF SE
  • 18.7. Biolchim Group by J.M. Huber Corporation
  • 18.8. BioLume, Inc.
  • 18.9. BlueBioTech GmbH
  • 18.10. Cellana Inc.
  • 18.11. Corbion N.V.
  • 18.12. DSM-Firmenich AG
  • 18.13. Earthrise Nutritionals LLC
  • 18.14. GeoMarine Biotechnologies (P) LTD
  • 18.15. GlycoMar Ltd.
  • 18.16. Marine Biopolymers Ltd.
  • 18.17. Marinova Pty Ltd
  • 18.18. Marshall Marine Products
  • 18.19. Nofima
  • 18.20. oceanBASIS GmbH
  • 18.21. Pharma Mar, S.A.
  • 18.22. PROLUME, LTD
  • 18.23. Seppic S.A.
  • 18.24. The GELITA Group
  • 18.25. Veramaris V.O.F.
  • 18.26. Xanthella Ltd.
  • 18.27. ZIVO Bioscience, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MARINE BIOTECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MARINE BIOTECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MARINE BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MARINE BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY BIOACTIVE COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY BIOACTIVE COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY BIOACTIVE COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY BIOMATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY BIOMATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY BIOMATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY CORALS & SPONGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY CORALS & SPONGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY CORALS & SPONGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY MARINE ALGAE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY MARINE ALGAE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY MARINE ALGAE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY MARINE FUNGI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY MARINE FUNGI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY MARINE FUNGI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY MARINE VIRUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY MARINE VIRUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY MARINE VIRUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY CULTURE-INDEPENDENT TECHNIQUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY CULTURE-INDEPENDENT TECHNIQUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY CULTURE-INDEPENDENT TECHNIQUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY ISOLATION & CULTIVATION OF MICROORGANISMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY ISOLATION & CULTIVATION OF MICROORGANISMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY ISOLATION & CULTIVATION OF MICROORGANISMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY AQUACULTURE & FISHERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY AQUACULTURE & FISHERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY AQUACULTURE & FISHERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY ENVIRONMENTAL HEALTH & HUMAN HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY ENVIRONMENTAL HEALTH & HUMAN HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY ENVIRONMENTAL HEALTH & HUMAN HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY FOOD SUPPLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY FOOD SUPPLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY FOOD SUPPLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY INDUSTRIAL PRODUCTS & PROCESSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY INDUSTRIAL PRODUCTS & PROCESSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY INDUSTRIAL PRODUCTS & PROCESSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY CHEMICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY CHEMICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY CHEMICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY COSMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY COSMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY COSMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY ENERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY ENERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY ENERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY FOOD INDUSTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY FOOD INDUSTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY FOOD INDUSTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY MEDICAL & PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY MEDICAL & PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY MEDICAL & PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS MARINE BIOTECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA MARINE BIOTECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 120. GCC MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 123. GCC MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. GCC MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. GCC MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 138. G7 MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. G7 MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. G7 MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. NATO MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 147. NATO MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. NATO MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NATO MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL MARINE BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES MARINE BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA MARINE BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA MARINE BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA MARINE BIOTECHNOLOGY MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA MARINE BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA MARINE BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA MARINE BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)